Norway · Delayed Price · Currency is NOK Observe Medical ASA Earnings Call Transcripts
Fiscal Year 2026
-
Significant growth achieved with 73% higher order intake and 92% net sales increase, driven by the launch of UnoMeter Safeti Max and expanded global distribution. Clinical validation and sustainability benefits support premium pricing, while digital and operational investments position the company for further market leadership.
-
Sales grew 80% year-on-year, driven by new product launches and expanded distribution, with the business now present in 46 countries and targeting a NOK 2.6 billion market. The company expects to reach cash positivity this year and continues to innovate with products like UnoMeter Safeti Max.
Fiscal Year 2025
-
Oona Meter products saw 61% growth and expanded to 44 countries, with order intake surpassing NOK 25 million. New infection control innovations and product launches are on track, while significant debt reduction and a new investor have strengthened financials.
-
A robust proprietary and partnered product strategy has positioned the business as a leader in urine output measurement, with a strong global distribution network and accelerating order intake. Key product launches and debt restructuring agreements support ambitions for profitability and growth.
Fiscal Year 2024
-
H1 2024 saw NOK 13.1 million in revenue and a gross margin of 38.2%, with the launch of UnoMeter Safeti Plus expected to drive future growth. A NOK 22 million private placement strengthened liquidity, and new partnerships and product launches are set to expand market reach.